A four-year, $3.4 million grant to investigate molecular mechanisms and therapeutic treatments for acute respiratory distress syndrome (ARDS) has been awarded to UTHealth Houston researchers by the ...
--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult patients with any type of virus induced ARDS including the ...
In a new report posted online in the American Journal of Respiratory and Critical Care Medicine, a global consensus conference of 32 critical care experts with broad international representation and ...
DUBLIN--(BUSINESS WIRE)--The "Global Acute Respiratory Distress Syndrome Market (2024 Edition): Market Size, Trends, Opportunities and Forecast by End-User, Mode of Administration, Treatment Mode, ...
The MarketWatch News Department was not involved in the creation of this content. Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human ...
Unlike current treatment methods, SWAZA-1 is noninvasive, simple to administer, and low-cost. The novel technology can be easily administered via nebulization, allowing for early intervention. This ...
Acute respiratory distress syndrome (ARDS) continues to be a tough nut to crack in critical care, taking lives despite years of research and better ventilator strategies. It is defined by acute ...
Bringing the newborn home is such a special and emotional experience for parents, and yet with it come some unexpected challenges. One concern is Newborn Respiratory Distress Syndrome, wherein the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback